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S U M M A R Y
Hepatitis B virus (HBV) vaccination has been recommended for all neonates in China since 1992. This
article reviews the impact of HBV vaccination throughout the past 20 years in China. Before the
introduction of the HBV vaccination program, approximately 9.8% of the general Chinese population
tested positive for hepatitis B virus surface antigen (HBsAg). Since 1992, vaccination coverage has
increased each year. In 1999, a National Expanded Programme on Immunization (EPI) review showed
that the immunization coverage with three doses of HBV vaccine was 70.7%, and reached 99.0% in
Beijing. The HBsAg carrier rate in the general population decreased to 7.2% in 2006. In particular, the
prevalence of HBsAg decreased to 2.3% among children aged 5–14 years and to 1.0% among children
younger than 5 years. In addition, the administration of the HBV vaccine may have reduced the risk of
hepatocellular carcinoma among adults. Despite the administration of hepatitis B immunoglobulin and
the HBV vaccine to children with HBsAg-positive mothers, the failure rate of HBV immunoprophylaxis
was 5–10%. In China, vaccine failure was related to HBV S gene mutation and inadequate administration
of HBV vaccine. The prevalence of HBV carriers in China was markedly reduced after the introduction of
the universal HBV vaccination program. If we immunize all susceptible individuals with the hepatitis B
vaccine (especially children), interrupt transmission, and provide antiviral treatment for existing HBV
carriers, the number of new cases may be reduced to close to zero in the future and this may eventually
result in the eradication of HBV.
 2011 International Society for Infectious Diseases. Published by Elsevier Ltd. All rights reserved.
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Hepatitis B virus (HBV) infection is a serious public health
problem worldwide and is a major cause of chronic hepatitis,
cirrhosis, and hepatocellular carcinoma (HCC).1 At least 2 billion
people are infected with HBV and among them 350–400 million
are chronic HBV carriers. An estimated 1 million people die each
year from acute and chronic sequelae secondary to HBV infection.2
Approximately 4.5 million new cases of HBV infection occur
worldwide each year, and 25% of these cases progress to liver
disease.3 There is a marked difference in the geographic distribu-
tion of carriers, ranging from 10–20% in Southeast Asia and Sub-
Saharan Africa to less than 1% in Northern Europe and America.1,4
Approximately 75% of chronic carriers live in Asia and the Western
Paciﬁc.1,4 In low endemic areas, most HBV infections are acquired
via horizontal transmission among adolescents and young adults.
Regarding areas of high endemicity, the infection is often acquired
during the preschool years, and the most common route of* Corresponding author. Tel.: +86 571 87236585; fax: +86 571 87236585.
E-mail address: ruanbing@zjwst.gov.cn (B. Ruan).
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doi:10.1016/j.ijid.2011.10.009transmission in Asiatic countries is perinatal and in African
countries is horizontal during childhood.2,4 The risk of becoming an
HBV carrier is 90% in cases of perinatal infection, between 25% and
30% for infected infants and children under 5 years of age, and less
than 10% for infected adults.2,4 More than a quarter of infants and
older children who acquire an HBV infection will eventually
develop HBV-related HCC or cirrhosis. Adults who have had a
chronic HBV infection since childhood develop HCC at a rate of 5%
per decade, which is 100–300-times the rate among uninfected
persons.1,4
In the People’s Republic of China, HCC is the second leading
cause of cancer mortality. Approximately 110 000 persons die each
year from HCC, which accounts for 45% of the deaths from HCC
worldwide.5,6 In China, the standardized annual death rate from
HCC was 11.00 per 100 000 persons in 1973–75, increasing to
17.83 per 100 000 persons in 1990–92, then remaining steady at
17.86 per 100 000 persons in 2004–05.7 Aging has contributed to
this increase in the death rate during the past 30 years, because
HCC develops most frequently in persons aged 40 years and older.8
However, since the introduction of HBV vaccination in 1992, the
mortality rate has remained steady in the setting of aging. The
major risk factor for HCC in China is clearly chronic HBV infection,ses. Published by Elsevier Ltd. All rights reserved.
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these two etiological agents are 11.34 for HBV and 4.28 for HCV
(p < 0.05).9 More than 70–80% of HCC cases in China are
attributable to HBV and approximately 20% of HCC patients test
positive for HCV RNA.10–12 Because less than 10% of HCC cases are
non-B and non-C, surveillance of hepatitis carriers is the most
important tool for the prevention of HCC in China.
Although current antiviral treatments using interferons or
nucleoside/nucleotide analogs are effective against chronic HBV,
chronic carriage of the virus is more difﬁcult to eliminate.
Considering that most HBV infections in China occur perinatally,
universal infant vaccination is the key to the elimination and
subsequent eradication of HBV.
The ﬁrst HBV vaccine, derived from human carrier plasma, was
approved for use in the USA in 1981. In 1991, the World Health
Organization (WHO) recommended that all countries implement a
policy of universal HBV vaccination by 1997.13Most countries have
incorporated universal HBV vaccination into their national infant
immunization programs. The estimated global coverage rate of
infant HBV vaccination increased from less than 1% in 1990 to 30%
in 2000, and from nearly 50% in 2004 to 69% in 2008.14 As of 2008,
177 of the 193 WHO member states (92%) had initiated HBV
vaccination programs.15 This program has reduced not only the
rate of persistent infection and the total prevalence of HBV in the
younger generation, but also the occurrence of childhood HCC and
fulminant hepatitis.16 In China, hepatitis B has signiﬁcantly
declined in the past decades as a result of the HBV vaccination
program and the introduction of other public health measures,
such as the use of universal precautions in medical settings and
blood screening tests. Thus, this article reviews the impact of HBV
vaccination in China over the past 20 years.
2. Strategy for the prevention of HBV infection in China
China is classiﬁed as an area of high HBV endemicity, and the
HBV vaccine has been available in China since 1982. The Ministry
of Health of China has implemented a series of regulations on the
management of hepatitis B vaccination since 1992. As a result, the
routine HBV immunization of infants was recommended in 1992;
however unlike other Expanded Programme on Immunization
(EPI) vaccines, families had to pay for the HBV vaccine. In 2001, the
central government of China decided to integrate HBV vaccination
into the EPI, requiring local authorities at all levels to provide free
HBV vaccine to all infants from 2002; however the families had to
pay the service fee for the vaccination procedure. The Chinese
government ﬁnally adopted a completely free HBV vaccination
program for all neonates in 2005.17
In China, most cases of HBV infection occur when the virus is
transmitted from carrier mothers to infants during the perinatal
period, and from other horizontal sources to infants and children.
Over the past 20 years, China has adopted a series of strategies to
eliminate HBV infection and prevent transmission of the virus.18
These strategies are outlined as follows: (1) Consistently strength-
en general newborn hepatitis B vaccination. To prevent perinatal
transmission, neonates born to hepatitis B surface antigen
(HBsAg)-positive mothers should receive a combination of
immunization with the hepatitis B vaccine (either 10 mg recombi-
nant yeast vaccine or 20 mg Chinese hamster oocyte (CHO)
vaccine) and hepatitis B immunoglobulin (HBIG; 100 IU) within
24 h after birth; within 12 h after delivery is also an option. By
combining hepatitis B vaccine together with the HBIG injection, a
95–97% protective rate could be achieved in those neonates born to
HBsAg-positive mothers. (2) Create a nationwide program that
provides ‘catch-up’ immunization with the HBV vaccine for
children who were not vaccinated at birth. (3) Encourage pregnant
women to determine their HBsAg status in hospital even thoughthis is not mandatory, and provide the vaccine for the high-risk
populations, increasing the vaccine dosage and number of shots for
patients or non-responders. (4) Provide immediate care to
individuals exposed to HBV by accident. For those who are
negative or who have an unknown status for the antibody to
the hepatitis B surface antigen (anti-HBs), a combination of the
hepatitis B vaccine and HBIG are given immediately after exposure
to the virus.
In China, the hepatitis B immunization coverage rate has
increased each year since 1992. Infant vaccination coverage with
both the timely birth dose and the complete vaccine series was
substantially higher among children born during 2003 than among
those born during 1997; timely birth-dose coverage increased
from 29.1% to 75.8%, and the HepB series completion increased
from 70.7% to 89.8%, with the highest in Beijing at 99%.19 A study
conducted in Zhejiang Province, which is located in the southeast
of China, showed that by 1997, the hepatitis B immunization
coverage rate for newborns receiving their ﬁrst dose reached
96.1%, and for those receiving three doses reached 93.0%.20 In
general, a protective antibody response occurs after the ﬁrst dose
in 30–50% of healthy adults aged 40 years or younger. This
protective response occurs in 75.0% of healthy adults after the
second dose, and in more than 90.0% of healthy adults after the
third dose.16 Data obtained from a Chinese survey revealed that
after completion of the three-dose HBV vaccination regimen,
approximately 90–95% of healthy individuals exhibited protective
concentrations of the anti-HBs antibody.21
3. Impact of HBV vaccination in China over a 20-year period
3.1. Changes in the prevalence of chronic HBV carriers
According to a national study published in the early 1990s, the
overall prevalence of chronic HBV carriage was approximately 9.8%
in 61 702 subjects in 30 provinces of China (range 4.5–17.9%)
before the introduction of the HBV vaccine.22 Liang et al.23 reported
that the prevalence of HBsAg positivity in 2002 was 8.5% in a
population of 46 167 people aged 10 years, born before the
vaccination program was introduced. Zhou24 launched a survey of
7451 public employees between 2003 and 2004 to evaluate HBV
infection. The results showed that the vaccinated population had a
lower HBsAg prevalence compared with the unvaccinated
individuals (3.1% vs. 8.3%). The study further discovered that the
risk of becoming an HBV carrier in the vaccinated cohort was
signiﬁcantly associated with incomplete HBV vaccination (for
those who received fewer than three doses of HBV vaccine). Tian
et al.25made a comparison of the HBV prevalence in 1983 and 2005
in Hebei Province. They reported that the overall prevalence of
HBsAg among 5460 subjects aged 1 year was 8.6% in 1995.
However in 2005, after 19 years of immunization with the vaccine,
the average HBsAg positive rate of 10 010 subjects was 5.3%. A
subgroup analysis revealed that the rate of HBsAg carriage among
subjects aged 1–19 years was 9.4% in 1995, while it was 1.5% in
2005. Hence, the rate of HBsAg carriage declined from 9.4% in 1995
to 1.5% in 2005, a reduction of 84.4%. Most of the subjects aged
1–19 years in the 2005 survey were born after the introduction of
the universal vaccination program. However, the rates of HBsAg
carriage among subjects older than 20 years during the same years
were 7.6% and 7.0%, respectively, a reduction of 8.4% from 1995 to
2005. For all years, the rates of HBsAg carriage were signiﬁcantly
lower among subjects aged 1–19 years than among subjects older
than 20 years. Wu et al.26 also conducted a study on the HBV
prevalence in people aged 1–49 years in 1999. They found that the
prevalence of HBsAg among children (age range 1–13 years; born
between 1986 and 1999) who were vaccinated as infants was
below 1%. The rate of HBsAg carriage among junior and senior high
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Figure 1. Comparison of the prevalence of hepatitis B surface antigen (HBsAg) in
1992 and 2006; HBV vaccination has been recommended for all neonates in China
since 1992.
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Figure 2. Comparison of the prevalence of antibody to hepatitis B core antigen (anti-
HBc) in 1992 and 2006; HBV vaccination has been recommended for all neonates in
China since 1992.
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was signiﬁcantly lower than the rate of HBsAg in people aged
20 years. People born between 1982 and 1985 were vaccinated as
school-age children, but people older than 20 years had not ever
been vaccinated. Although many epidemiological studies have
assessed HBV infection in China, most of the studies have been
based on unrepresentative or small populations from selected
communities. The Chinese Ministry for Health, Center for Disease
Control and Prevention, performed national hepatitis serosurveys
in 1992 and 2006 among the population aged 1–59 years to
investigate the epidemiological characteristics of HBV infection in
China.27 As the surveys were based on a representative sample of
the entire nation and used a stratiﬁed multistage probability
sampling design, these data provide a comprehensive picture of
the distribution of HBV in China.
Data obtained from the ﬁrst national survey in 1992 revealed
that the rates of HBsAg seropositivity in children aged 4 years
were 10.7% in males and 8.5% in females. Among children and
adolescents aged 5–14 years, the seropositivity rates were 12.4% in
males and 8.9% in females. The peak age for seropositivity was
10–14 years for both males and females, after which time the rates
remained the same until the subjects reached 50–59 years. The
rates then decreased in both males and females.28 Data obtained
from the most recent national HBV survey in China, which was
undertaken in 2006,27 after 14 years of HBV vaccination
implementation, revealed that the prevalence of HBsAg in the
general population was 7.2% in 2006 and was 1.0% among males
and females aged 4 years (Figure 1). The prevalence of HBsAg was
2.3% in children and adolescents aged 5–14 years, and the total
number of HBV carriers was estimated to be more than 93 million,
among whom 30 million were patients with chronic hepatitis B.
According to these nationwide surveys, the prevalence of HBsAg
positivity in persons aged 4 years decreased from 9.7% in 1992
to 1.0% in 2006. The rate of HBsAg carriage among subjects aged
5–14 years declined from 10.7% in 1992 to 2.3% in 2006. A
sustained decline in HBV infection is expected in the future,
whereupon the prevalence of HBV infection in China will
eventually be as low as that in Western countries.
3.2. Changes in HBV surface antibody and HBV core antibody
positivity
In 1992, the ﬁrst national hepatitis serosurvey found that the
weighted anti-HBs seropositive rate was 27.4%: 27.5% in males and
28.9% in females.28 The rate of HBV surface antibody (anti-HBs) in
3419 children aged 1–14 years increased sharply, from 37.2% in
1992 to 65.0% in 2002 in Guangdong Province following the
introduction of the hepatitis B vaccine into the EPI in 1992.29 In1999, Ma et al.30 also examined the prevalence of anti-HBs among
1727 children in Hebei Province and found that the anti-HBs
seropositive rate was 93.9% among children aged 1–3 years, 57.8%
among children aged 4–10 years, and 16.2% among children aged
11–14 years. Lei et al.31 reported in the middle 2000s that the
serological epidemiology of anti-HBs for children aged 1–6 years in
the Zhujiang Delta Area was 65.8%, which was similar to that in
Guangdong Province. In 2005, Yu et al.32 reported that the anti-HBs
positive rate in Wuhan City was 42.4% in 1992 in children aged
1–3 years, increasing to 79.1% in 1999. By 2003 it reached 83.2%;
the positive rate increased by 49.0% when compared with that of
children of the same age in 1992. A 2006 survey of national
immunity conducted by the Chinese government revealed that the
anti-HBs prevalence was 60.0% among children born during the
period 1992–2005 (aged 1–13 years).33
Regarding the change in antibody to the hepatitis B core antigen
(anti-HBc) positivity, during the 1980s, the proportion of chronic
HBsAg carriage attributable to perinatal transmission was
estimated at 13–20%. Thereafter, the prevalence of anti-HBc
increased with increasing age. The anti-HBc positivity rate was
nearly 30.0% among children younger than 10 years. Among adults
in their forties, the infection rate reached approximately 60.0%.34
After the introduction of the vaccine program, Chen et al.35
reported that the anti-HBc seropositive rate in 2002 was 11.9%
among children aged 3–5 years, 9.5% among children aged 6–10
years, and 12.7% among children aged 11–15 years. During the late
2000s, the prevalence of anti-HBc decreased with decreasing age
and was less than 10% in the population younger than 15 years.36
These data may reﬂect the effects of universal HBV vaccination in
China. In the national survey of 2006,27 the proportion of anti-HBc
was highest in adults aged 50–59 years (50.0%) and decreased with
decreasing age (Figure 2).
3.3. Changes in hepatitis B e antigen (HBeAg) status among HBsAg-
positive persons
In the national survey of HBV in 1992, the age-speciﬁc
prevalence of HBeAg among HBsAg carriers was 32.7%. Children
aged 1–14 years had the highest prevalence of 53.3%. After that, the
prevalence decreased with age to 12.3% in people aged 40–59
years.28 In the most recent survey in 2006, we found that among
HBsAg-positive children aged <15 years, the proportion positive
for HBeAg was still high (>68%). HBeAg decreased with age to
15.0% among persons age 40–59 years. These are similar to
percentages found in 1992. Hence, over the past 20 years, a change
in the HBeAg-positive rate is not evident. The currently available
hepatitis B vaccines should continue, particularly ensuring that
timely birth doses are given to all children.
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Figure 3. Average annual incidence of hepatocellular carcinoma in children aged
6–14 years before and after the start of the HBV vaccination program; HBV
vaccination was recommended in 1984 in Taiwan.
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HCC is one of the most common cancers worldwide (ranking
within the top 10). In some parts of Asia it represents the ﬁrst or
second most common cancer and is a major public health
problem.37
The treatment of liver cancer may be difﬁcult because most
patients, especially those in less developed areas, are diagnosed at
an advanced stage, at which time the disease is not amenable to
potential curative therapy. Thus prevention is the key to reducing
the occurrence of liver cancer and its related mortality. With
respect to liver cancer, hepatitis B vaccination early in life before
infection occurs provides a good example of a primary prevention
measure. At a WHO meeting in 1983, the evidence for an
association between the carrier state of HBV infection and liver
cancer was sufﬁciently strong to justify the use of a vaccine against
this infection as a means of preventing this cancer.38
In 1998, a large-scale cohort study39 performed in Korea
reported that HBV vaccination protected against the development
of HCC in adult men. This study found that the incidence of HCC
was lower in the vaccinated group than in the unvaccinated group
and suggested that HBV vaccination signiﬁcantly decreases the
incidence of HCC, even in adulthood. Importantly, a Taiwanese
study demonstrated a decline in the incidence of HCC in children
after the implementation of universal hepatitis B vaccination.40
Mass vaccination against hepatitis B was launched in 1984 in
Taiwan. The study reported that the average annual incidence of
HCC in children aged 6–14 years declined from 0.70 per 100 000
children between 1981 and 1986 to 0.57 between 1986 and 1990,
and to 0.36 between 1990 and 1994 (p < 0.01), after the
vaccination program was started (Figure 3). The corresponding
rates of mortality from HCC also decreased. A more recent study
from Taiwan by Chang et al.41 also revealed the effectiveness of the
universal HBV immunization program to prevent HCC. In each of
the study age groups, the incidence rates of HCC were signiﬁcantly
(p < 0.001) lower in the vaccinated birth cohorts compared with
the unvaccinated (Table 1). The data suggest that 75% of HCC in
children in Taiwan might be prevented by hepatitis B immuniza-
tion. These are long-term follow-up studies that can verify that
hepatitis B vaccination not only protected children from becoming
carriers but also protected them against HCC. Along with a
decrease in HBsAg carrier status, the development of HCC is
expected to decrease in the near future.
4. Failure of immunoprophylaxis
Before the introduction of the HBV vaccine, nearly 90% of
infants born to HBeAg-positive mothers were infected at birth.42,43
By administering HBIG and the HBV vaccine to all neonates born
from HBsAg-positive mothers, 88–95% of all cases of perinatalTable 1
Incidence rates of hepatocellular carcinoma in Taiwan among children aged 6–9, 10–1
hepatitis B virus vaccination program in 1984
Age at diagnosis, y Birth year Hepatocellular carcino
Incidence rate (per 10
6–9 1973–1979 0.51 
1979–1984 0.47 
1984–1998 0.15 
10–14 1968–1979 0.60 
1979–1984 0.50 
1984–1994 0.19 
15–19 1963–1979 0.52 
1979–1984 0.80 
1984–1989 0.16 
95% CI, 95% conﬁdence interval.transmission of HBV could be eliminated.43,44 However, despite
the adequate administration of HBIG and the HBV vaccine at birth,
about 5–10% of cases of perinatal transmission of HBV could not be
completely prevented.44,45 Although the cause of prophylaxis
failure is still unclear, high levels of maternal viremia and
intrauterine infections probably contribute.44–49 According to
studies reported in China,50,51 vertical transmission in infants
was uniquely associated with the mother’s HBeAg titer and HBV
DNA levels. HBsAg-positive rates in infants according to the HBeAg
status and HBV DNA levels of their HBsAg-positive mothers are
shown in Tables 2 and 3.51 Among the 178 neonates born to
mothers whose HBeAg titer was 1:100 or greater and HBV-DNA
was 125 pg/ml or greater, 31 (17.4%) were HBsAg-positive.
Conversely, of the infants born to mothers whose HBeAg titer
was less than 1:100 or HBV-DNA load was less than 125 pg/ml, one
was HBsAg-positive. Wang et al. also reported that the mean HBV
DNA level of mothers whose babies became infected with HBV was
signiﬁcantly higher than the mean level of those mothers whose
babies did not become infected with HBV (2.14  105 copies/ml vs.
2.39  106 copies/ml; p = 0.04).52 Liu et al.50 reported that a high
HBV DNA viral load (107 copies/ml) was the most important risk
factor for the failure of immunization; they determined that the
danger of vertical transmission was low when the HBV DNA load
was less than 105 copies/ml in the mother, but increased as the
level rose to 107, 108, and 109 copies/ml. These studies reveal the
importance of perinatal transmission of HBV from HBeAg-positive
and high HBV DNA level mothers to their children. The same
conclusions have been reached in other countries. In Korea, Song
et al.53 evaluated the failure of HBV immunoprophylaxis in
144 children who received HBIG and the HBV vaccine, and who
were born to HBsAg-positive mothers with detectable HBV
DNA. Among the 144 participants, 17 (11.8%) experienced4, and 15–19 years, born before and after the launch of the Taiwanese universal
ma p-Value
0 000 person-years) Rate ratio (95% CI)
1 (referent)
0.93 (0.59–1.46) 0.74
0.30 (0.18–0.42) <0.001
1 (referent)
0.84 (0.60–1.17) 0.29
0.32 (0.21–0.49) <0.001
1 (referent)
1.55 (1.17–2.04) 0.001
0.30 (0.16–0.58) <0.001
Table 2
Changes in vaccine failure rate in the newborn according to maternal HBeAg titer
Maternal HBeAg titers Mother–child pairs Vaccine failure rate, n (%)
<1:50 56 0 (0)
1:50 20 0 (0)
1:100 16 2 (12.5)
1:200 16 5 (31.3)
1:400 70 25 (35.7)
HBeAg, hepatitis B e antigen.
Table 3
Changes in vaccine failure rate in the newborn according to maternal HBV DNA titer
Maternal HBV
DNA titers (pg/ml)
Mother–child
pairs
Vaccine failure
rate, n (%)
<125 86 1 (1.2)
125–1000 24 6 (25)
1000–8000 60 21 (35)
8000 8 4 (50)
HBV, hepatitis B virus.
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failure was 12% among children born to mothers who were HBsAg-
positive, 0% in those born to HBeAg-negative mothers, 21% in those
born to HBeAg-positive mothers, 0% in those born to mothers with
undetectable HBV DNA, and 27% in those born to mothers with
detectable HBV DNA. A study by Kang et al.54 reported that the
failure rate of HBV immunoprophylaxis was 7.4% and that all such
cases had been born to HBeAg-positive mothers. According to a
national survey in 2006,33 among the neonates born in 2005, the
rate of weighted three-dose coverage of hepatitis B vaccine
reached 93.4%. Despite the high rate of three-dose coverage, the
positivity rate of anti-HBs was only 84.5%. Approximately 10% of
newborns experienced immunoprophylaxis failure, deﬁned as
anti-HBs seronegativity. These reports conﬁrm again that maternal
transmission is the primary reason for vaccine failure and that it is
this primary problem that must be addressed. Therefore, maternal
HBeAg and HBV DNA levels should be assessed prior to childbirth
to identify children at high risk of immunoprophylaxis failure. The
effectiveness of strategies to reduce maternal HBV activity during
the perinatal period should also be further elucidated.
Another mechanism of vaccine failure involves HBV surface
gene mutants. The immune pressure of hepatitis B immunization
and HBIG promotes the selection of HBV surface gene mutants. In
particular, S gene HBV mutants (i.e., the prototype G145R
mutation, in which a single amino acid substitution of glycine
to arginine occurs at amino acid 145 of the ‘a’ determinant of the
surface antigen) have been identiﬁed in Italy and elsewhere.55–57
Such mutants can potentially escape neutralizing anti-HBs
antibodies and infect vaccinated people. In Taiwan, the prevalence
of surface gene mutants was found to be approximately 20.0% in
HBsAg carrier children.56 However the prevalence of HBV surface
gene mutants across the nation of China remains unclear. A survey
undertaken in eastern China50 found that the total mutation rate
was only 12.5% (2/16) in vaccination failed children. Hu et al.58
reported that among immunoprophylaxis failed children, the
prevalence of amino acid substitutions was 20.0%. Wang et al.59
also reported that nucleotide diversity rates were 11.4% in the
children of Jiangsu Province. This might be because the HBV S gene
mutation rates differed with the geography and the years of HBV
vaccination. However, the mutation rate was clearly lower than
that in children who failed to be protected by perinatal prophylaxis
in other countries (Singapore 39.0%, Japan 30.8%, USA 25.5%),60–62
and higher than that in Korea.63 Therefore, compared with
previous studies in other nations, gene surface variants do notappear to play an important role in perinatal immunoprophylaxis
failure in China. Chen reported that the presence of vaccine escape
mutants does not seem to threaten the ongoing hepatitis B control
strategies worldwide.16 Worthy of note is the fact that the current
hepatitis B vaccines can protect chimpanzees from infection with a
mutant virus.64 Hence, the currently available hepatitis B vaccines
can be continued in all countries including China.
Inadequate administration of HBV vaccine may be a cause of
perinatal immunoprophylaxis failure. A national survey undertak-
en in 200565 reported that the coverage with a timely birth dose
was only 69.6% in rural areas and 86.9% in urban areas.
Furthermore, most hospitals refrained from administering HBIG
to mothers of unknown HBsAg status until a complete report was
obtained. Such a delay in providing the initial dose of the vaccine
increases the risk of HBV infection in the child. Increasing the HBIG
coverage rates among infants born to HBsAg-positive mothers is
also an important way to prevent mother-to-infant transmission.
Data obtained from the national study also revealed that the HepB
series completion rate of infants was approximately 90.7% in rural
areas and 95.0% in urban areas.65 Therefore, the rate of vaccination
coverage must be increased to minimize the risk of HBV
transmission, and the timely administration of the HBV vaccine
must be ensured. These data suggest that considerable variation
exists in the administration of perinatal prophylaxis and that
failure to provide appropriate immunoprophylaxis remains an
important cause of perinatal HBV infection, especially among
infants born in rural areas of China.
5. Strategies towards the eradication of hepatitis B
As is known to us, infection with HBV consists of three
components: an infectious source, a susceptible host, and an
established route of transmission.66 Because humans are the only
reservoir of HBV, it is not impossible that a comprehensive control
strategy could eventually lead to the eradication of the virus. To
begin with, existing HBV carriers can now be treated effectively67
and viral load can decrease to undetectable levels, so that infection
does not spread rampantly. However, prolonged use of current
nucleos(t)ide analogs against HBV still poses the problem of viral
resistance, and the cost of long-term treatment is still high.67
Another important strategy is to interrupt the transmission route
through education of the public and medical personnel, although
changes in high-risk human behaviors are often difﬁcult to achieve.
In China, we should place an emphasis on more and better
screening of HBsAg in pregnant women. Screening pregnant
women will result in the early detection of high-risk infants for
HBV infection, so that measures to prevent mother-to-infant
transmission can be taken. The most effective strategy, however, is
to immunize all susceptible individuals with the hepatitis B
vaccine, especially children.66,68 Universal hepatitis B vaccination
in childhood can prevent not only chronic HBV infection in high
endemic areas, but also acute HBV infection in low endemic areas
of China. Therefore, it should be recommended at all levels of
government, regardless of HBV endemicity. A recent survey
revealed that HBIG may also play an important role. Xu et al.69
reported that it is effective and safe to prevent intrauterine
infection of HBV with HBIG from the 28th week of pregnancy in
women who are positive for HBeAg and HBsAg. This is particularly
signiﬁcant in China, as most HBV carriers are infected by mother-
to-infant transmission. Many researchers from China70 and other
countries71 have also reported that the addition of HBIG to the
recombinant vaccine for neonates will signiﬁcantly increase the
prevalence of anti-HBs and the protection against HBV infection in
comparison with HBV vaccine alone.
In summary, the combined efforts of universal vaccination,
HBIG, antiviral treatment, and interruption of transmission make
Z. Luo et al. / International Journal of Infectious Diseases 16 (2012) e82–e88 e87the elimination of HBV infection plausible and may eventually
result in the eradication of HBV. To reach this goal, all efforts need
to be supported adequately, and a long-term commitment from
both government and non-governmental organizations is essen-
tial. This support should be lasting and overcome the existing
backlog of HBV carriers in the population of China. The goal of
eradicating HBV is plausible, but every endeavor should to be
pursued to make this become a reality.
6. Conclusions
Hepatitis B vaccination has effectively reduced the infection
and chronicity rates of HBV and related complications. However,
despite adequate administration of HBIG and the HBV vaccine in
children with HBsAg-positive mothers, the vaccine failure rate was
5–10%. Vaccine failure was related to HBV S gene mutation and
inadequate administration of HBV vaccine in China. Despite
considerable efforts to reduce HBV infection via the universal
vaccination of all newborn and school-age children, a large
proportion of the population was previously infected with HBV
and still harbors the virus. Although difﬁcult, the eradication of
HBV remains possible in China in the future, considering that
humans are the only reservoir of HBV.
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